• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

成人特发性血小板减少性紫癜脾切除术:一项评估长期血小板计数反应、反应预测及手术并发症的系统评价

Splenectomy for adult patients with idiopathic thrombocytopenic purpura: a systematic review to assess long-term platelet count responses, prediction of response, and surgical complications.

作者信息

Kojouri Kiarash, Vesely Sara K, Terrell Deirdra R, George James N

机构信息

Hematology-Oncology Section, Department of Medicine, College of Medicine, The University of Oklahoma Health Sciences Center, Oklahoma City, USA.

出版信息

Blood. 2004 Nov 1;104(9):2623-34. doi: 10.1182/blood-2004-03-1168. Epub 2004 Jun 24.

DOI:10.1182/blood-2004-03-1168
PMID:15217831
Abstract

Splenectomy has been a standard treatment for adult patients with idiopathic thrombocytopenic purpura (ITP) for more than 50 years. However, the durability of responses, the ability to predict who will respond, and the frequency of surgical complications with splenectomy all remain uncertain. To better interpret current knowledge we systematically identified and reviewed all 135 case series, 1966 to 2004, that described 15 or more consecutive patients who had splenectomy for ITP and that had data for 1 of these 3 outcomes. Complete response was defined as a normal platelet count following splenectomy and for the duration of follow-up with no additional treatment. Forty-seven case series reported complete response in 1731 (66%) of 2623 adult patients with follow-up for 1 to 153 months; complete response rates did not correlate with duration of follow-up (r = -0.103, P = .49). None of 12 preoperative characteristics that have been reported consistently predicted response to splenectomy. Mortality was 1.0% (48 of 4955 patients) with laparotomy and 0.2% (3 of 1301 patients) with laparoscopy. Complication rates were 12.9% (318 of 2465) with laparotomy and 9.6% (88 of 921 patients) with laparoscopic splenectomy. Although the risk of surgery is an important consideration, splenectomy provides a high frequency of durable responses for adult patients with ITP.

摘要

50多年来,脾切除术一直是成年特发性血小板减少性紫癜(ITP)患者的标准治疗方法。然而,反应的持久性、预测谁会有反应的能力以及脾切除术后手术并发症的发生率仍不确定。为了更好地解读现有知识,我们系统地识别并回顾了1966年至2004年期间的所有135个病例系列,这些系列描述了15名或更多连续接受ITP脾切除术的患者,并且有这三种结果之一的数据。完全缓解定义为脾切除术后血小板计数正常且在随访期间无需额外治疗。47个病例系列报告了2623名成年患者中的1731名(66%)达到完全缓解,随访时间为1至153个月;完全缓解率与随访时间无关(r = -0.103,P = 0.49)。12种术前特征中没有一种能始终如一地预测对脾切除术的反应。开腹手术的死亡率为1.0%(4955例患者中的48例),腹腔镜手术的死亡率为0.2%(1301例患者中的3例)。开腹手术的并发症发生率为12.9%(2465例中的318例),腹腔镜脾切除术的并发症发生率为9.6%(921例患者中的88例)。虽然手术风险是一个重要的考虑因素,但脾切除术能为成年ITP患者提供较高频率的持久反应。

相似文献

1
Splenectomy for adult patients with idiopathic thrombocytopenic purpura: a systematic review to assess long-term platelet count responses, prediction of response, and surgical complications.成人特发性血小板减少性紫癜脾切除术:一项评估长期血小板计数反应、反应预测及手术并发症的系统评价
Blood. 2004 Nov 1;104(9):2623-34. doi: 10.1182/blood-2004-03-1168. Epub 2004 Jun 24.
2
Management of adult patients with persistent idiopathic thrombocytopenic purpura following splenectomy: a systematic review.脾切除术后成人持续性特发性血小板减少性紫癜患者的管理:一项系统评价
Ann Intern Med. 2004 Jan 20;140(2):112-20. doi: 10.7326/0003-4819-140-3-200402030-00012.
3
Systematic review: efficacy and safety of rituximab for adults with idiopathic thrombocytopenic purpura.系统评价:利妥昔单抗治疗成人特发性血小板减少性紫癜的疗效与安全性
Ann Intern Med. 2007 Jan 2;146(1):25-33. doi: 10.7326/0003-4819-146-1-200701020-00006.
4
Sertindole for schizophrenia.用于治疗精神分裂症的舍吲哚。
Cochrane Database Syst Rev. 2005 Jul 20;2005(3):CD001715. doi: 10.1002/14651858.CD001715.pub2.
5
Intravenous versus inhalational maintenance of anaesthesia for postoperative cognitive outcomes in elderly people undergoing non-cardiac surgery.非心脏手术老年患者术后认知结局:静脉麻醉维持与吸入麻醉维持的比较
Cochrane Database Syst Rev. 2018 Aug 21;8(8):CD012317. doi: 10.1002/14651858.CD012317.pub2.
6
Cost-effectiveness of using prognostic information to select women with breast cancer for adjuvant systemic therapy.利用预后信息为乳腺癌患者选择辅助性全身治疗的成本效益
Health Technol Assess. 2006 Sep;10(34):iii-iv, ix-xi, 1-204. doi: 10.3310/hta10340.
7
Nivolumab for adults with Hodgkin's lymphoma (a rapid review using the software RobotReviewer).纳武单抗用于成人霍奇金淋巴瘤(使用RobotReviewer软件进行的快速综述)
Cochrane Database Syst Rev. 2018 Jul 12;7(7):CD012556. doi: 10.1002/14651858.CD012556.pub2.
8
Exercise-based cardiac rehabilitation for coronary heart disease.基于运动的冠心病心脏康复。
Cochrane Database Syst Rev. 2021 Nov 6;11(11):CD001800. doi: 10.1002/14651858.CD001800.pub4.
9
Chimeric antigen receptor (CAR) T-cell therapy for people with relapsed or refractory diffuse large B-cell lymphoma.嵌合抗原受体 (CAR) T 细胞疗法治疗复发或难治性弥漫性大 B 细胞淋巴瘤患者。
Cochrane Database Syst Rev. 2021 Sep 13;9(9):CD013365. doi: 10.1002/14651858.CD013365.pub2.
10
Prophylactic platelet transfusions prior to surgery for people with a low platelet count.血小板计数低的患者在手术前进行预防性血小板输注。
Cochrane Database Syst Rev. 2018 Sep 17;9(9):CD012779. doi: 10.1002/14651858.CD012779.pub2.

引用本文的文献

1
Patient survey in immune thrombocytopenia (ITP): Identifying unmet needs related to treatment and disease control in patients living in the United States.免疫性血小板减少症(ITP)患者调查:确定美国患者在治疗和疾病控制方面未满足的需求。
Br J Haematol. 2025 Sep;207(3):1038-1046. doi: 10.1111/bjh.20257. Epub 2025 Aug 17.
2
Evaluating rilzabrutinib in the treatment of immune thrombocytopenia.评估利扎布替尼治疗免疫性血小板减少症的效果。
Immunotherapy. 2025 Aug;17(11):767-782. doi: 10.1080/1750743X.2025.2545170. Epub 2025 Aug 11.
3
Pediatric splenectomy for hematologic disorders: two-decade experience and prophylactic cholecystectomy outcomes.
小儿血液系统疾病脾切除术:二十年经验及预防性胆囊切除术结果
BMC Surg. 2025 Aug 9;25(1):359. doi: 10.1186/s12893-025-03107-0.
4
Splenectomy: still a life-saving treatment in immune thrombocytopenia.脾切除术:在免疫性血小板减少症中仍是一种挽救生命的治疗方法。
Haematologica. 2025 Jul 1;110(7):1451-1453. doi: 10.3324/haematol.2025.287512.
5
Rilzabrutinib for the Treatment of Immune Thrombocytopenia.利扎布替尼用于治疗免疫性血小板减少症。
Eur J Haematol. 2025 Jul;115(1):4-15. doi: 10.1111/ejh.14425. Epub 2025 Apr 13.
6
Predictors of Splenectomy Response in Immune Thrombocytopenia: A Multicentric Italian Study.免疫性血小板减少症脾切除术反应的预测因素:一项意大利多中心研究。
J Clin Med. 2024 Dec 25;14(1):30. doi: 10.3390/jcm14010030.
7
Treatment of Immune Thrombocytopenia: Contextualization from a Historical Perspective.免疫性血小板减少症的治疗:历史视角下的情境化
Hematol Rep. 2024 Jun 26;16(3):390-412. doi: 10.3390/hematolrep16030039.
8
Splenomegaly and Response to Splenectomy in Immune Thrombocytopenia.免疫性血小板减少症中的脾肿大及脾切除反应
J Clin Med. 2024 Jun 26;13(13):3712. doi: 10.3390/jcm13133712.
9
Safety and efficacy of danazol in immune thrombocytopenia: a systematic review.达那唑治疗免疫性血小板减少症的安全性和有效性:一项系统评价。
Res Pract Thromb Haemost. 2024 May 17;8(4):102444. doi: 10.1016/j.rpth.2024.102444. eCollection 2024 May.
10
The Challenge for a Correct Diagnosis of Refractory Thrombocytopenia: ITP or MDS with Isolated Thrombocytopenia?难治性血小板减少症正确诊断面临的挑战:免疫性血小板减少症还是伴有孤立性血小板减少症的骨髓增生异常综合征?
Cancers (Basel). 2024 Apr 11;16(8):1462. doi: 10.3390/cancers16081462.